Medical Oncology 2, Istituto Oncologico Veneto IRCCS, Padova, Italy; Department of Surgery, Oncology and Gastroenterology, University of Padova, Italy.
Medical Oncology, AULSS 7 Pedemontana, Santorso Hospital and Bassano Hospital, Vicenza, Italy.
Eur J Cancer. 2021 Apr;147:120-127. doi: 10.1016/j.ejca.2021.01.021. Epub 2021 Feb 3.
Coronavirus disease 2019 (COVID-19) pandemic started in Italy with clusters identified in Northern Italy. The Veneto Oncology Network (Rete Oncologica Veneta) licenced dedicated guidelines to ensure proper care minimising the risk of infection in patients with cancer. Rete Oncologica Veneta covID19 (ROVID) is a regional registry aimed at describing epidemiology and clinical course of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in patients with cancer.
Patients with cancer diagnosis and documented SARS-CoV-2 infection are eligible. Data on cancer diagnosis, comorbidities, anticancer treatments, as well as details on SARS-CoV-2 infection (hospitalisation, treatments, fate of the infection), have been recorded. Logistic regression analysis was applied to calculate the association between clinical/laboratory variables and death from any cause.
One hundred seventy patients have been enrolled. The median age at time of the SARS-CoV infection was 70 years (25-92). The most common cancer type was breast cancer (n = 40). The majority of the patients had stage IV disease. Half of the patients had two or more comorbidities. The majority of the patients (78%) presented with COVID-19 symptoms. More than 77% of the patients were hospitalized and 6% were admitted to intensive care units. Overall, 104 patients have documented resolution of the infection. Fifty-seven patients (33%) have died. In 29 cases (17%), the cause of death was directly correlated to SARS-CoV-2 infection. Factors significantly correlated with the risk of death were the following: Eastern Cooperative Oncology Group performance status (PS), age, presence of two or more comorbidities, presence of dyspnoea, COVID-19 phenotype ≥ 3, hospitalisation, intensive care unit admission, neutrophil/lymphocyte ratio and thrombocytopenia.
The mortality rate reported in this confirms the frailty of this population. These data reinforce the need to protect patients with cancer from SARS-CoV-2 infection.
2019 年冠状病毒病（COVID-19）疫情始于意大利，在意大利北部发现了聚集病例。威尼托肿瘤网络（Rete Oncologica Veneta）获得许可，制定了专门的指南，以确保癌症患者得到适当的护理，最大限度地降低感染风险。威尼托肿瘤网络 covID19（ROVID）是一个区域登记处，旨在描述癌症患者中严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）感染的流行病学和临床过程。
符合条件的患者为癌症诊断并确诊 SARS-CoV-2 感染。记录了癌症诊断、合并症、抗癌治疗以及 SARS-CoV-2 感染的详细信息（住院、治疗、感染结局）。应用逻辑回归分析计算临床/实验室变量与任何原因死亡之间的关联。
共纳入 170 例患者。感染 SARS-CoV 时的中位年龄为 70 岁（25-92）。最常见的癌症类型是乳腺癌（n=40）。大多数患者为 IV 期疾病。一半的患者有两种或两种以上合并症。大多数患者（78%）有 COVID-19 症状。超过 77%的患者住院，6%入住重症监护病房。总体而言，有 104 例患者记录了感染的痊愈。57 例（33%）死亡。在 29 例（17%）中，死亡原因与 SARS-CoV-2 感染直接相关。与死亡风险显著相关的因素包括：东部合作肿瘤学组表现状态（PS）、年龄、存在两种或两种以上合并症、存在呼吸困难、COVID-19 表型≥3、住院、入住重症监护病房、中性粒细胞/淋巴细胞比值和血小板减少症。
本报告的死亡率证实了该人群的脆弱性。这些数据加强了保护癌症患者免受 SARS-CoV-2 感染的必要性。
